UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preventing and Managing Toxicities of High‐Dose Methotrexate

The oncologist (Dayton, Ohio), 2016-12, Vol.21 (12), p.1471-1482

2016

Volltextzugriff (PDF)

Cancer, Inflammation, and Therapy: Effects on Cytochrome P450-Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents

Clinical pharmacology and therapeutics, 2014-10, Vol.96 (4), p.449-457

2014

Volltextzugriff (PDF)

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2018-05, Vol.36 (14), p.1389-1395

2018

Volltextzugriff (PDF)

Withaferin A inhibits breast cancer invasion and metastasis at sub‐cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation

International journal of cancer, 2011-12, Vol.129 (11), p.2744-2755

2011

Volltextzugriff (PDF)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

Journal of Oncology Pharmacy Practice, 2020-09, Vol.26 (6), p.1461-1474

2020

Volltextzugriff (PDF)

American Society of Clinical Oncology Statement: Biosimilars in Oncology

Journal of clinical oncology, 2018-04, Vol.36 (12), p.1260-1265

2018

Volltextzugriff (PDF)

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

Clinical pharmacokinetics, 2019-04, Vol.58 (4), p.431-449

2019

Volltextzugriff (PDF)

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Blood, 2014-08, Vol.124 (7), p.1038-1046

2014

Volltextzugriff (PDF)

Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer

The Annals of pharmacotherapy, 2021-07, Vol.55 (7), p.921-931

2021

Volltextzugriff (PDF)

Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO- Friends Recommendations

Clinical cancer research, 2021-05, Vol.27 (9), p.2430-2434

2021

Volltextzugriff (PDF)

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

BMC cancer, 2019-08, Vol.19 (1), p.857-857, Article 857

2019

Volltextzugriff (PDF)

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey

JCO oncology practice, 2020-07, Vol.16 (7), p.417-421

2020

Volltextzugriff (PDF)

Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment

The Journal of pharmacology and experimental therapeutics, 2019-05, Vol.369 (2), p.291-299

2019

Volltextzugriff (PDF)

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells

Blood, 2014-05, Vol.123 (21), p.3269-3276

2014

Volltextzugriff (PDF)

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

Clinical cancer research, 2021-05, Vol.27 (9), p.2400-2407

2021

Volltextzugriff (PDF)

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e001006

2020

Volltextzugriff (PDF)

Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast

The oncologist (Dayton, Ohio), 2023-12, Vol.28 (12), p.1055-1063

2023

Volltextzugriff (PDF)

The earlier the better? Or better late than never? Dose optimization in oncology

JNCI : Journal of the National Cancer Institute, 2023-05, Vol.115 (5), p.485-487

Harvey, R Donald

2023

Volltextzugriff (PDF)

Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing

Therapeutic advances in medical oncology, 2019-01, Vol.11, p.1758835918818335-1758835918818335

2019

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

Journal of clinical oncology, 2010-06, Vol.28 (18), p.3015-3022

2010

Volltextzugriff (PDF)

Reply to S.D. Lucio

Journal of clinical oncology, 2018-07, Vol.36 (20), p.2127-2127

2018

Volltextzugriff (PDF)

Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma

British journal of cancer, 2020-10, Vol.123 (8), p.1228-1234

2020

Volltextzugriff (PDF)

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Frontiers in oncology, 2022-01, Vol.11, p.786120-786120

2022

Volltextzugriff (PDF)

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Journal of clinical oncology, 2010-10, Vol.28 (29), p.4507-4512

2010

Volltextzugriff (PDF)

Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma

Journal of Oncology Pharmacy Practice, 2019-04, Vol.25 (3), p.613-622

2019

Volltextzugriff (PDF)

1 – 25 von 650

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(570)
Mit Volltextzugriff
(531)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(648)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Preventing and Managing Toxicities of High‐Dose Methotrexate

Cancer, Inflammation, and Therapy: Effects on Cytochrome P450-Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

Withaferin A inhibits breast cancer invasion and metastasis at sub‐cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

American Society of Clinical Oncology Statement: Biosimilars in Oncology

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer

Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO- Friends Recommendations

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey

Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast

The earlier the better? Or better late than never? Dose optimization in oncology

Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

Reply to S.D. Lucio

Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma

Aktive Filter

Suchergebnisse filtern